Skip to main content
Generic Alternatives

Biosimilars in Canada: The Generic Version of Biologics

Biosimilars can save Canadians 25% to 50% on expensive biologic drugs. Learn what biosimilars are, how they are approved, and which ones are available in Canada.

TransparentMedz Team
March 15, 2026
4 min read
735 words

What Are Biosimilars?

Biosimilars are the biologic equivalent of generic drugs — but with an important distinction. While a generic drug is a chemical copy of a brand-name medication (identical molecule), a biosimilar is a highly similar version of a biologic drug. Biologic drugs are made from living cells, which means exact replication is not possible. Instead, biosimilars must demonstrate that they are so similar to the original that any differences are clinically meaningless.

Think of it this way: a generic version of atorvastatin is chemically identical to Lipitor. A biosimilar version of Humira (adalimumab) is highly similar to Humira but not molecularly identical — yet it works the same way in your body.

Why Biosimilars Matter

Biologic drugs are among the most expensive medications in Canada. Many cost $15,000 to $50,000 per year. Biosimilars typically cost 25% to 50% less, creating enormous savings for patients, insurers, and provincial drug plans.

Cost Comparison: Biologics vs Biosimilars

Biologic (Brand)BiosimilarAnnual Brand CostAnnual Biosimilar CostSavings
Humira (adalimumab)Hadlima, Hyrimoz, Hulio$20,000 - $24,000$12,000 - $16,00030 - 40%
Remicade (infliximab)Inflectra, Renflexis$25,000 - $35,000$15,000 - $22,00035 - 40%
Enbrel (etanercept)Brenzys, Erelzi$18,000 - $22,000$11,000 - $14,00035 - 40%
Lantus (insulin glargine)Basaglar$2,500 - $3,500$1,800 - $2,50025 - 30%
Herceptin (trastuzumab)Ogivri, Herzuma, Trazimera$45,000 - $55,000$28,000 - $35,00035 - 40%

How Health Canada Approves Biosimilars

Biosimilar approval in Canada is handled through a dedicated pathway that requires extensive evidence:

Required Evidence

  • Analytical studies: Detailed comparison of the biosimilar's structure and function to the reference biologic
  • Non-clinical studies: Laboratory and sometimes animal testing to confirm similar biological activity
  • Clinical studies: Human trials (usually Phase III) to confirm similar efficacy and safety
  • Immunogenicity testing: Ensuring the biosimilar does not trigger a different immune response
  • The Approval Standard

    Health Canada requires that a biosimilar demonstrate no clinically meaningful differences from the reference biologic in terms of:

    • Safety (same side effect profile)
    • Efficacy (same therapeutic effect)
    • Quality (consistent manufacturing)

    Provincial Biosimilar Switching Programs

    Several Canadian provinces have implemented mandatory switching programs that transition patients from expensive biologics to approved biosimilars:

    ProvinceProgram StatusKey Details
    British ColumbiaActive since 2019First province to implement; covers 7 drug categories
    AlbertaActive since 2020Mandatory switch for public drug plan beneficiaries
    OntarioActive since 2022Phased rollout across multiple drug categories
    QuebecActive since 2022Applies to RAMQ beneficiaries
    New BrunswickActive since 2021Covers select biologic categories
    These programs have been clinically successful. British Columbia's experience showed that over 95% of patients who switched to biosimilars experienced no change in disease control.

    Biosimilars Available in Canada

    As of 2026, Health Canada has approved biosimilars for several major biologics:

    Autoimmune Conditions (Rheumatoid Arthritis, Crohn's, Psoriasis)

    • Adalimumab biosimilars: Hadlima, Hyrimoz, Hulio, Idacio, Simlandi, Yuflyma
    • Infliximab biosimilars: Inflectra, Renflexis, Avsola
    • Etanercept biosimilars: Brenzys, Erelzi

    Diabetes

    • Insulin glargine biosimilar: Basaglar

    Cancer

    • Trastuzumab biosimilars: Ogivri, Herzuma, Trazimera
    • Bevacizumab biosimilar: Mvasi
    • Rituximab biosimilars: Truxima, Riximyo

    Common Concerns About Switching

    Will the biosimilar work as well?

    Clinical evidence from millions of patients worldwide shows that biosimilars are equally effective as the original biologic. The switching programs in BC and Alberta have confirmed this in Canadian patients.

    What about side effects?

    Biosimilars have the same side effect profile as the reference biologic. There is no evidence of increased adverse events in patients who switch.

    Can I switch back?

    If you experience issues after switching, your doctor can switch you back to the original biologic. In practice, this is rarely necessary.

    How to Learn More About Your Options

    If you are currently taking an expensive biologic, talk to your doctor or specialist about whether a biosimilar alternative is available. You can also use TransparentMedz to compare pricing on biosimilars and their reference biologics to understand the potential savings for your specific treatment.

    Share this article

    Ready to save on your prescriptions?

    Compare prices across Canadian pharmacies and find the lowest cost for your medication.

    Compare Prices Now